Fig. 7: CDX2 attenuates the Wnt/β-catenin pathway through direct transcriptional activation of the expression of GSK-3β and Axin2 in colon cancer cells. | Cell Death & Disease

Fig. 7: CDX2 attenuates the Wnt/β-catenin pathway through direct transcriptional activation of the expression of GSK-3β and Axin2 in colon cancer cells.

From: CDX2 inhibits the proliferation and tumor formation of colon cancer cells by suppressing Wnt/β-catenin signaling via transactivation of GSK-3β and Axin2 expression

Fig. 7Fig. 7

a, b Axin2 promoter activities in CDX2-knockdown (a) and CDX2-overexpressing (b) HT-29 cells. c, d Axin2 promoter activities in CDX2-knockdown (c) and CDX2-overexpressing (d) Caco-2 cells. e, f GSK-3β promoter activities in CDX2-knockdown (e) and CDX2-overexpressing (f) HT-29 cells. g, h GSK-3β promoter activities in CDX2-knockdown (g) and CDX2-overexpressing (h) Caco-2 cells. i, j Enrichment level of CDX2 binding to specific regions of the Axin2 enhancer in CDX2-knockdown and CDX2-overexpressing HT-29 (i) and Caco-2 cells (j) determined by the qChIP assay. k, l Enrichment level of CDX2 binding to specific regions of the GSK-3β promoter in CDX2-knockdown and CDX2-overexpressing HT-29 (k) and Caco-2 cells (l) determined by the qChIP assay. All data are the mean ± SD of three independent experiments. *P < 0.05

Back to article page